Champions Oncology (NASDAQ:CSBR) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.32 and traded as low as $5.65. Champions Oncology shares last traded at $5.65, with a volume of 895 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Champions Oncology has a consensus rating of “Sell”.

Champions Oncology Price Performance

The stock’s fifty day moving average is $5.95 and its 200-day moving average is $6.32. The stock has a market cap of $78.48 million, a PE ratio of -35.31 and a beta of 0.41.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Champions Oncology by 1.9% during the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 6,229 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Champions Oncology by 28.7% in the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Champions Oncology in the 2nd quarter valued at $103,000. Essex Investment Management Co. LLC acquired a new position in shares of Champions Oncology in the 4th quarter valued at $126,000. Finally, Jane Street Group LLC acquired a new position in shares of Champions Oncology in the 1st quarter valued at $200,000. 41.30% of the stock is currently owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.